Events Partner Content Operationalize: Expanded Access Programs Summit Operational Expanded Access Programs Summit
News Novartis pays $1bn upfront for Huntington's drug from PTC Novartis has made a return to the Huntington's disease stage by licensing an oral mRNA splicer from PTC Therapeutics for $1 billion upfront.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.